MX2019000844A - Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123. - Google Patents
Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123.Info
- Publication number
- MX2019000844A MX2019000844A MX2019000844A MX2019000844A MX2019000844A MX 2019000844 A MX2019000844 A MX 2019000844A MX 2019000844 A MX2019000844 A MX 2019000844A MX 2019000844 A MX2019000844 A MX 2019000844A MX 2019000844 A MX2019000844 A MX 2019000844A
- Authority
- MX
- Mexico
- Prior art keywords
- binding
- antibody
- binding protein
- bispecific antibody
- proteins specifically
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a una proteína de tipo anticuerpo que se une específicamente a CD3 y CD123. La invención también se refiere a composiciones farmacéuticas que comprende proteína de unión de tipo anticuerpo y el uso de dichas composiciones farmacéuticas y proteína de tipo anticuerpo para tratar el cáncer. La invención además se refiere a ácidos nucleicos aislados, vectores y células huésped que comprenden una secuencia que codifica la proteína de unión de tipo anticuerpo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16305923 | 2016-07-18 | ||
PCT/EP2017/068020 WO2018015340A1 (en) | 2016-07-18 | 2017-07-17 | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019000844A true MX2019000844A (es) | 2019-07-04 |
Family
ID=56507555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019000844A MX2019000844A (es) | 2016-07-18 | 2017-07-17 | Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123. |
Country Status (24)
Country | Link |
---|---|
US (1) | US20190241657A1 (es) |
EP (1) | EP3484924A1 (es) |
JP (2) | JP7071329B2 (es) |
KR (1) | KR20190028771A (es) |
CN (1) | CN109715665A (es) |
AR (1) | AR109264A1 (es) |
AU (1) | AU2017299125A1 (es) |
BR (1) | BR112019000770A2 (es) |
CA (1) | CA3030943A1 (es) |
CL (1) | CL2019000119A1 (es) |
CO (1) | CO2019001367A2 (es) |
CR (1) | CR20190072A (es) |
DO (1) | DOP2019000011A (es) |
EA (1) | EA201990321A1 (es) |
EC (1) | ECSP19011185A (es) |
IL (1) | IL264248A (es) |
MA (1) | MA45680A (es) |
MX (1) | MX2019000844A (es) |
PE (1) | PE20190514A1 (es) |
PH (1) | PH12019500122A1 (es) |
SG (1) | SG11201900400QA (es) |
TN (1) | TN2019000015A1 (es) |
TW (1) | TWI790206B (es) |
WO (1) | WO2018015340A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2824167T3 (es) | 2015-01-23 | 2021-05-11 | Sanofi Sa | Anticuerpos anti-CD3, anticuerpos anti-CD123 y anticuerpos biespecíficos que se unen específicamente a CD3 y/o CD123 |
TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
JP2022513402A (ja) * | 2018-10-30 | 2022-02-07 | マクロジェニクス,インコーポレーテッド | 血液悪性腫瘍の治療のための二重特異性cd123×cd3ダイアボディ |
MA55305A (fr) * | 2019-03-11 | 2022-01-19 | Janssen Biotech Inc | Anticorps bispécifiques anti-v béta 17/anti-cd123 |
CN111349163A (zh) | 2020-02-05 | 2020-06-30 | 北京智仁美博生物科技有限公司 | 针对cd123的单克隆抗体 |
TW202200618A (zh) * | 2020-03-17 | 2022-01-01 | 美商西雅圖免疫公司 | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 |
US11965024B2 (en) | 2020-09-11 | 2024-04-23 | Janssen Biotech, Inc. | Methods and compositions for modulating beta chain mediated immunity |
WO2022165171A1 (en) | 2021-01-28 | 2022-08-04 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
CN113368232B (zh) * | 2021-06-02 | 2022-08-26 | 上海交通大学 | 多特异性抗原结合蛋白及其应用 |
CA3224408A1 (en) * | 2021-08-06 | 2023-02-09 | Rosalba LEPORE | Discernible cell surface protein variants for use in cell therapy |
US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
DE69032484D1 (de) | 1989-10-27 | 1998-08-20 | Arch Dev Corp | Zusammensetzungen und deren verwendung zur förderung der immunopotentiation |
US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
DE69131017T2 (de) | 1990-12-20 | 1999-07-15 | Ixsys Inc | Optimierung von bindenden proteinen |
CA2156725A1 (en) | 1993-02-22 | 1994-09-01 | Warren S. Pear | Production of high titer helper-free retroviruses by transient transfection |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
JP3946256B2 (ja) | 1995-09-11 | 2007-07-18 | 協和醗酵工業株式会社 | ヒトインターロイキン5受容体α鎖に対する抗体 |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US6177078B1 (en) | 1995-12-29 | 2001-01-23 | Medvet Science Pty Limited | Monoclonal antibody antagonists to IL-3 |
DE19721700C1 (de) | 1997-05-23 | 1998-11-19 | Deutsches Krebsforsch | Mutierter OKT3-Antikörper |
PT1071752E (pt) | 1998-04-21 | 2003-11-28 | Micromet Ag | Polipeptidos especificos para cd19xcd3 e suas utilizacoes |
AU5003001A (en) | 2000-03-06 | 2001-09-17 | Univ Kentucky Res Found | Methods to impair hematologic cancer progenitor cells and compounds related thereto |
CA2698203C (en) | 2007-08-29 | 2018-09-11 | Sanofi-Aventis | Humanized anti-cxcr5 antibodies, derivatives thereof and their use |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
RU2547600C2 (ru) * | 2008-10-01 | 2015-04-10 | Эмджен Рисерч (Мьюник) Гмбх | Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью |
TWI622597B (zh) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
CN103748114B (zh) | 2011-08-23 | 2017-07-21 | 罗切格利卡特公司 | T细胞活化性双特异性抗原结合分子 |
EP4053162A1 (en) * | 2012-05-18 | 2022-09-07 | Aptevo Research and Development LLC | Bispecific scfv immunofusion (bif) binding to cd123 and cd3 |
EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
CN105793285A (zh) * | 2013-12-10 | 2016-07-20 | 豪夫迈·罗氏有限公司 | 多亚基结构的亚基的结合结构域用于将药物活性实体靶向递送至多亚基结构的用途 |
EA037647B1 (ru) | 2014-09-05 | 2021-04-27 | Янссен Фармацевтика Нв | Агенты, связывающиеся с cd123, и виды их применения |
CA2967426A1 (en) * | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and tumor antigens |
ES2824167T3 (es) * | 2015-01-23 | 2021-05-11 | Sanofi Sa | Anticuerpos anti-CD3, anticuerpos anti-CD123 y anticuerpos biespecíficos que se unen específicamente a CD3 y/o CD123 |
-
2017
- 2017-07-14 TW TW106123588A patent/TWI790206B/zh active
- 2017-07-17 AR ARP170101993A patent/AR109264A1/es unknown
- 2017-07-17 EA EA201990321A patent/EA201990321A1/ru unknown
- 2017-07-17 JP JP2019502257A patent/JP7071329B2/ja active Active
- 2017-07-17 CR CR20190072A patent/CR20190072A/es unknown
- 2017-07-17 WO PCT/EP2017/068020 patent/WO2018015340A1/en unknown
- 2017-07-17 MA MA045680A patent/MA45680A/fr unknown
- 2017-07-17 CN CN201780056945.7A patent/CN109715665A/zh active Pending
- 2017-07-17 US US16/318,599 patent/US20190241657A1/en not_active Abandoned
- 2017-07-17 CA CA3030943A patent/CA3030943A1/en active Pending
- 2017-07-17 BR BR112019000770A patent/BR112019000770A2/pt not_active IP Right Cessation
- 2017-07-17 KR KR1020197004345A patent/KR20190028771A/ko not_active Application Discontinuation
- 2017-07-17 EP EP17749380.6A patent/EP3484924A1/en not_active Withdrawn
- 2017-07-17 SG SG11201900400QA patent/SG11201900400QA/en unknown
- 2017-07-17 PE PE2019000065A patent/PE20190514A1/es not_active Application Discontinuation
- 2017-07-17 AU AU2017299125A patent/AU2017299125A1/en not_active Abandoned
- 2017-07-17 MX MX2019000844A patent/MX2019000844A/es unknown
- 2017-07-17 TN TNP/2019/000015A patent/TN2019000015A1/en unknown
-
2019
- 2019-01-15 IL IL264248A patent/IL264248A/en unknown
- 2019-01-16 CL CL2019000119A patent/CL2019000119A1/es unknown
- 2019-01-16 PH PH12019500122A patent/PH12019500122A1/en unknown
- 2019-01-16 DO DO2019000011A patent/DOP2019000011A/es unknown
- 2019-02-15 EC ECSENADI201911185A patent/ECSP19011185A/es unknown
- 2019-02-15 CO CONC2019/0001367A patent/CO2019001367A2/es unknown
-
2022
- 2022-05-02 JP JP2022075664A patent/JP2022105138A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EA201990321A1 (ru) | 2019-06-28 |
TN2019000015A1 (en) | 2020-07-15 |
US20190241657A1 (en) | 2019-08-08 |
SG11201900400QA (en) | 2019-02-27 |
TWI790206B (zh) | 2023-01-21 |
AU2017299125A1 (en) | 2019-03-07 |
DOP2019000011A (es) | 2019-05-15 |
IL264248A (en) | 2019-02-28 |
CO2019001367A2 (es) | 2019-02-19 |
PH12019500122A1 (en) | 2019-04-15 |
EP3484924A1 (en) | 2019-05-22 |
JP2022105138A (ja) | 2022-07-12 |
ECSP19011185A (es) | 2019-02-28 |
JP7071329B2 (ja) | 2022-05-18 |
AR109264A1 (es) | 2018-11-14 |
CR20190072A (es) | 2019-06-25 |
WO2018015340A1 (en) | 2018-01-25 |
MA45680A (fr) | 2019-05-22 |
CN109715665A (zh) | 2019-05-03 |
CA3030943A1 (en) | 2018-01-25 |
CL2019000119A1 (es) | 2019-06-14 |
KR20190028771A (ko) | 2019-03-19 |
JP2019531701A (ja) | 2019-11-07 |
PE20190514A1 (es) | 2019-04-10 |
BR112019000770A2 (pt) | 2019-07-02 |
TW201811830A (zh) | 2018-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500122A1 (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
MX2021011697A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123. | |
MX2022015901A (es) | Proteinas de union biespecificas y usos de las mismas. | |
SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
MX2022001222A (es) | Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos. | |
JOP20200313A1 (ar) | أجسام مضادة dll3-cd3 ثنائية الخاصية | |
MX2023007045A (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos. | |
PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
MX2021015182A (es) | Casetes optimizados de expresion del gen humano del factor viii de coagulacion y su uso. | |
MX2019012223A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
MX2017001403A (es) | Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido. | |
PH12019500571A1 (en) | Anti-pd-1 antibodies | |
JOP20220079A1 (ar) | بروتين ربط متعددة الخصوصية لمعالجة السرطان | |
PH12020550483A1 (en) | Anti-apoc3 antibodies and methods of use thereof | |
PH12019502449A1 (en) | Anti-jagged1 antigen binding proteins | |
MX2020001287A (es) | Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos. | |
TW202417514A (zh) | 雙特異性結合蛋白及其用途 |